Systemic Sclerosis Pregnancies: High Livebirth Rates Mask Significant Risks of Placental Insufficiency and Postpartum Disease Progression
Posted innews OB/GYN & Women's Health Rheumatology

Systemic Sclerosis Pregnancies: High Livebirth Rates Mask Significant Risks of Placental Insufficiency and Postpartum Disease Progression

The French GR2 prospective study reveals that while 91% of pregnancies in systemic sclerosis result in livebirths, patients face significantly higher risks of pre-eclampsia, fetal growth restriction, and severe postpartum hemorrhage, with nearly 40% experiencing maternal disease worsening.
Posted inAnesthesiology Diabetes & Endocrinology news

European Perioperative Diabetes Care: Significant Practice Variation Impacts 30-Day Recovery Outcomes

The MOPED study of over 6,000 European patients reveals significant international variations in perioperative diabetes management. Findings demonstrate that higher preoperative HbA1c levels and practice inconsistencies are linked to fewer days at home within 30 days of surgery, highlighting an urgent need for clinical harmonization.
Posted inCritical Care Neurology news

Rising Hospital Mortality and Escalating Rates of Life-Sustaining Therapy Withdrawal in Critically Ill TBI Patients: A 15-Year Analysis

A 15-year observational study of over 45,000 TBI patients reveals a significant increase in hospital mortality and a tripling of life-sustaining therapy withdrawal, alongside rising rates of hypoxaemia, raising urgent questions about ethical frameworks and neurocritical care management.
Posted inDiabetes & Endocrinology Internal Medicine news

Precision Diabetology Validated: Algorithm for SGLT2i and DPP4i Selection Performs Accurately Across Major UK Ethnicity Groups

A retrospective cohort study validates an algorithm for choosing between SGLT2 and DPP4 inhibitors across diverse UK ethnicity groups, confirming its accuracy for precision medicine while highlighting the necessity of minor recalibration to optimize performance in different populations.
Posted inHematology-Oncology news Oncology

MRD-Guided Intensification: A Tailored Approach to First-Line Chronic Lymphocytic Leukaemia Treatment

The HOVON 158/NEXT STEP phase 2 trial demonstrates that a measurable residual disease (MRD)-guided intensification strategy using ibrutinib and obinutuzumab significantly deepens remissions in first-line CLL patients who do not achieve deep responses with initial ibrutinib-venetoclax, while sparing early responders from additional toxicity.